Suggested remit: To appraise the clinical and cost effectiveness of low-dose atropine eye drops within its marketing authorisation for treating myopia in people 3 to 14 years.
- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Rationale:
- Scoping commenced.
- Process:
- STA Standard
- ID number:
- 6517
Provisional Schedule
- Committee meeting: 1:
- 08 July 2026
- Expected publication:
- 03 September 2026
Project Team
- Project lead
- Kate Moore
Email enquiries
If you have any queries please email TACommD@nice.org.uk
- External Assessment Group:
- School of Health and Related Research (ScHARR), University of Sheffield
Stakeholders
- Companies sponsors
- Santen (low-dose atropine eye drops [Ryjunea])
- Others
- Department of Health and Social Care
- NHS England
- Patient carer groups
- Myopia Focus
- Professional groups
- British & Irish Paediatric Ophthalmology and Strabismus Association
- British and Irish Orthoptic Society
- College of Optometrists
- Royal College of Ophthalmologists
- Royal College of Physicians
- Associated public health groups
- None
- Comparator companies
- None
- General commentators
- All Wales Therapeutics and Toxicology Centre
- British National Formulary
- Department of Health - Northern Ireland
- Healthcare Improvement Scotland
- Medicines and Healthcare products Regulatory Agency
- NHS Wales Joint Commissioning Committee
- Scottish Medicines Consortium
- Welsh Government
- Relevant research groups
- None
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 25 November 2025 | Invitation to participate |
| 16 June 2025 | The NICE Prioritisation Board (PB) met on Monday 16 June 2025 to consider the findings of the scoping exercise for this topic. PB subsequently agreed that low-dose atropine eye drops for treating myopia in people 3 to 14 years, should be selected for evaluation and ministerial referral from the Department of Health and Social Care (DHSC) will now be sought |
| 24 March 2025 - 23 April 2025 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: ID6517 |
| 24 March 2025 | In progress |
| 12 December 2024 | Awaiting development |
| 12 December 2024 | Topic selection. . |
For further information on our processes and methods, please see our CHTE processes and methods manual